Immune Response to COVID-19 Vaccination in People with Multiple Sclerosis

Serologic response is induced in most MS patients but is attenuated by some disease-modifying therapies.

For patients taking immunosuppressive or immunomodulatory drugs — including multiple sclerosis (MS) disease-modifying therapies (DMTs) — the effect on vaccine response is unclear. Now, two groups of investigators have examined the effect of DMTs on immune response to SARS-CoV-2 vaccination in people with MS.

In the first study, from Italy, Tortorella and colleagues compared the immune response to full vaccination of 78 healthcare workers (HCWs) with that of 108 MS patients, according to DMT received. Among the MS patients, 35 received fingolimod, 28 received IFN ß, 25 received ocrelizumab, and 20 received cladribine.

Results were as follows:

Response to receptor binding domain (RBD) antibodies was lower in MS patients who received ocrelizumab …

Reviewing Author

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

Immune Response to COVID-19 Vaccination in People with Multiple Sclerosis

Topics

Reviewing Author